In general, squamous patients with NSCLC bear a heavier tumor mutational burden with exception of targetable genomic mutations (e.g., EGFR, KRAS, or ROS1) than nonsquamous patients with NSCLC (Rizvi et al., 2015). This evidence concerns the gene EGFR and neoplasm.